Eli Lilly and Co. reported data from a second Phase III study showing that postmenopausal women who took arzoxifene, a drug candidate for osteoporosis, had increased bone-mineral density in the hips and spine compared with those who got placebo. Lilly said it plans to seek FDA clearance for the treatment and conclude another trial involving 9,000 patients later this year.

Full Story:
Bloomberg, Reuters

Related Summaries